Double-blind randomized placebo-controlled trial to evaluate the efficacy and safety of short-course low-dose oral prednisolone in pityriasis rosea.

Journal: The Journal Of Dermatological Treatment
Treatment Used: short-course low-dose oral prednisolone
Number of Patients: 0
MediFind Summary

Overview: The purpose of the study was to evaluate the efficacy and safety of short-course low-dose oral prednisolone in symptomatic pityriasis rosea of onset of less than 5 days and compare it with placebo

Conclusion: Oral corticosteroids, even in low-dose and for a short tapering course should not be the first line of therapy for pityriasis rosea.

Abstract

Objective: To evaluate the efficacy and safety of short-course low-dose oral prednisolone in symptomatic pityriasis rosea (PR) of onset <5 days and compare it with placebo.

Methods: Placebo-controlled randomized double-blind study design with the treatment group receiving tapering doses of oral prednisolone over 2 weeks and the control group receiving a placebo. Outcome measures evaluated were subsidence of patient-perceived pruritus, improvement in rash quantified by a specific score, adverse effects and relapse at 12 weeks.

Results: The improvement in the pruritus score as well as objective rash score were much better in the prednisolone-treated group. No adverse effects reported in either group. The relapse rate at 12 weeks was much higher in the prednisolone treated group.

Conclusions: Oral corticosteroids, even if used in low-dose and for a short tapering course should not be the first line of therapy for PR. The only justified indication may be extensive and highly symptomatic lesions of PR.

Authors
Sidharth Sonthalia, Akshy Kumar, Vijay Zawar, Adity Priya, Pravesh Yadav, Sakshi Srivastava, Atula Gupta
Relevant Conditions

Leprosy, Pityriasis Rosea

Similar Latest Advances